We’ve not yet tested it on every type of cancer, but it’s more successful than chemo and it’s much more easily tolerated by the patient.

In a trial of more than 350 patients, published in the New England Journal of Medicine, 36% treated with the immunotherapy drug nivolumab were alive after one year compared with 17% who received chemotherapy.
Patients also experienced fewer side effects from immunotherapy.